GlaukosGKOS +2.31%81 OCF Margin % is -8.32% as of Mar. 2026. GuruFocus rates GKOS with a GF Score™ of 81/100 and a GF Value™ of $135.34 (Fairly Valued). The stock has 6 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Glaukos ranks worse than 63.19% on this metric.
The historical rank and industry rank for Glaukos's OCF Margin % or its related term are showing as below:
GKOS'
s OCF Margin % Range Over the Past 10 Years
Min: -18.35 Med: -1.54 Max: 16.38
Current: -1.59
During the past 13 years, the highest OCF Margin % of Glaukos was 16.38%. The lowest was -18.35%. And the median was -1.54%.
GKOS's OCF Margin % is ranked worse than 63.19% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 5.86
vs GKOS: -1.59
Glaukos OCF Margin % Related Terms
Glaukos OCF Margin % Historical Data
* Premium members only.
The historical data trend for Glaukos's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Glaukos's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glaukos OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Glaukos's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glaukos (GKOS) has a OCF Margin % of -8.32% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Glaukos and its competitors. According to the industry distribution chart, Glaukos ranks #515 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 63.2%.
Is Glaukos' OCF Margin % too high?
Glaukos' current OCF Margin % is -8.32%. Based on the distribution chart, Glaukos ranks #515 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Glaukos has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' OCF Margin % compare to LIVN and BIO?
According to the Medical Devices & Instruments industry distribution chart, Glaukos ranks #515 out of 815 companies for OCF Margin %. This places Glaukos in the lower half of its industry. The industry median OCF Margin % is 5.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.86, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Glaukos and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glaukos's current OCF Margin % is -8.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Fairly Valued. The stock's GF Value™ is $135.34, compared to a current price of $137.76 — trading 1.8% above its estimated fair value. The current OCF Margin % is -8.32%. Glaukos' overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Glaukos (GKOS), the current OCF Margin % is -8.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glaukos (GKOS) Overvalued in 2026?
Based on GuruFocus' analysis, Glaukos stock appears to be overvalued.
The current stock price of $137.76 is trading 1.8% above its estimated GF Value™ of $135.34.
GuruFocus considers Glaukos to be Fairly Valued.
Key valuation signals for GKOS:
OCF Margin %: -8.32%
GF Value™: $135.34 vs. price of $137.76 (1.8% above fair value)
No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
81GF Score
Get the complete analysis for GKOS
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GKOS has been successfully added to your 
